In vitro activity of iclaprim and comparison agents tested against Neisseria gonorrhoeae including medium growth supplement effects

被引：0
作者：
Jones, Ronald N. [1 ]
Biedenbach, Douglas J. [1 ]
Sader, Helio S. [1 ]
机构：
[1] JMI Labs, N Liberty, IA USA
来源：
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2009年 / 63卷 / 03期
关键词：
Iclaprim; N; gonorrhoeae; Resistance; STD; DIAMINOPYRIMIDINE; SUSCEPTIBILITY; INHIBITORS; PENICILLIN; JAPAN;
D O I：
10.1016/j.diagmicrobio.2008.04.002
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Iclaprim is a novel diaminopyrimidine currently in phase III clinical development. This study was conducted to determine the activity of iclaprim compared with trimethoprim and other commonly prescribed drug classes against a comprehensive collection of 156 Neisseria gonorrhoeae, including subsets of organisms resistant to beta-lactam and fluoroquinolones (> 60%). Iclaprim (MIC50/90, 4/8 mu g/mL) was 16-fold more potent than trimethoprim (MIC50/90, 64/> 04 mu g/mL), and medium growth supplements did not adversely influence activity. Lack of cross-resistances for iclaprim with other commonly used therapies could make iclaprim an alternative for several sexually transmitted diseases (gonococci, Chlamydia trachomatis). (c) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码：339 / 341
页数：3
相关论文
共 19 条
[1]  
[Anonymous], 2003, Commun Dis Intell Q Rep, V27, P488
[2]  
Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1041
[3]  
Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1
[4]  
Clinical and Laboratory Standards Institute, 2018, METH DIL ANT SUSC TE
[5]  
CLSI Clinical and Laboratory Standards Institute, 2008, CLSI document M100-S18
[6]  
del Rio C., 2007, Morbidity and Mortality Weekly Report, V56, P332
[7]   Dihydrofolate reductase inhibitors as antibacterial agents [J].
Hawser, S ;
Lociuro, S ;
Islam, K .
BIOCHEMICAL PHARMACOLOGY, 2006, 71 (07) :941-948
[8]   Remarkable increase in central Japan in 2001-2002 of Neisseria gonorrhoeae isolates with decreased susceptibility to penicillin, tetracycline, oral cephalosporins, and fluoroquinolones [J].
Ito, M ;
Yasuda, M ;
Yokoi, S ;
Ito, SI ;
Takahashi, Y ;
Ishihara, S ;
Maeda, SI ;
Deguchi, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (08) :3185-3187
[9]   Activity of faropenem tested against Neisseria gonorrhoeae isolates including fluoroquinolone-resistant strains [J].
Jones, RN ;
Critchley, IA ;
Whittington, WLH ;
Janjic, N ;
Pottumarthy, S .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2005, 53 (04) :311-317
[10]   STANDARDIZATION OF DISK DIFFUSION AND AGAR DILUTION SUSCEPTIBILITY TESTS FOR NEISSERIA-GONORRHOEAE - INTERPRETIVE CRITERIA AND QUALITY-CONTROL GUIDELINES FOR CEFTRIAXONE, PENICILLIN, SPECTINOMYCIN, AND TETRACYCLINE [J].
JONES, RN ;
GAVAN, TL ;
THORNSBERRY, C ;
FUCHS, PC ;
GERLACH, EH ;
KNAPP, JS ;
MURRAY, P ;
WASHINGTON, JA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1989, 27 (12) :2758-2766
12